MedTrace Logo

Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score

NCT07257796 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-12-02

No results posted yet for this study

Summary

The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring.

This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).

Conditions

  • Intestinal Metaplasia of Gastric Mucosa
  • Artificial Intelligence
  • Endoscopy

Interventions

DIAGNOSTIC_TEST

The diagnostic performance of AI system and endoscopists

Eligible patients will undergo independent EGGIM score assessment by both endoscopists and the AI system.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07257796 on ClinicalTrials.gov